AI-redesigned antibody fragments show a route to targeting proteins inside cells
University of Essex researchers and international collaborators report using AI-guided protein redesign to convert 672 antibodies into stable intracellular antibody fragments, known as intrabodies. The work, published in Nature Communications, identifies electrical charge as a key determinant of whether such fragments remain functional inside human cells. The molecules are to be made freely available for research on proteins linked to Alzheimer’s, Parkinson’s, Huntington’s disease and motor neurone disease.
The story
Researchers at the University of Essex, working with international collaborators, developed a method for redesigning antibody fragments so that they can remain stable and work inside human cells. Conventional antibodies generally operate outside cells; the redesigned fragments, called intrabodies, are intended to bind disease-related proteins in the intracellular environment. According to the University of Essex material carried by ScienceDaily, the researchers compared properties of millions of antibodies with those of human proteins found inside cells and identified electrical charge as a factor affecting intracellular stability. They then used AI-powered protein redesign software to alter antibody fragments’ charge properties. The team reports converting 672 antibodies into intrabodies capable of targeting disease-related proteins. The study, “Reliable repurposing of the antibody interactome inside the cell,” is listed as published in Nature Communications. The work was funded by the MND Association and led by Dr. Caitlin O’Shea and Dr. Gareth Wright of the University of Essex School of Life Sciences. The researchers say the redesigned molecules will be made freely available to other scientists. The report frames them as potential tools for studying proteins associated with Alzheimer’s, Parkinson’s, Huntington’s disease and motor neurone disease, also called MND.
Why it matters
Many biological processes implicated in neurodegenerative disease occur within cells, while ordinary antibodies typically cannot reliably operate there. A dependable way to adapt antibodies for intracellular use could therefore give laboratories more direct ways to test how particular proteins behave and interact in their native cellular setting. The reported ability to repurpose existing antibodies is also practically relevant: it could build on molecules already created through prior biomedical research. For patients, however, the consequence is indirect at this stage; the work supplies a possible starting point for research and treatment development rather than demonstrating a therapy.
Evidence and context
The source says Alzheimer’s, Parkinson’s, Huntington’s disease and MND can involve cognitive impairment, memory problems, loss of muscle control and death, and that there are no cures for these conditions. It also reports that they affect more than one million people in the UK alone, though it does not provide a disease-by-disease breakdown or a global estimate. The central technical obstacle addressed here is intracellular access: proteins relevant to these diseases may be active inside neurons, where standard antibodies generally do not function. The MND Association’s chief scientist said combining intrabody work with emerging gene-therapy techniques could potentially create strategies aimed at molecular targets inside neurons. That is an expert view on a future application, not evidence that such a combined treatment has been tested.
Limits and unknowns
The result is limited by its stage of development. The supplied material describes redesigned antibody fragments and their ability to target important disease-related proteins, but does not report animal efficacy data, human testing, delivery methods, dosing, safety findings or evidence that the intrabodies alter disease progression. It also does not establish that all 672 redesigned molecules will be equally useful for every protein target or disease model. Intracellular stability addresses one barrier, but turning an intrabody into a treatment would still require a reliable way to deliver it to the relevant cells and to evaluate unintended effects.
Follow the story
Share it, watch the explainer, or continue with the reporting trail.
AI-redesigned antibody fragments show a route to targeting proteins inside cells
A short visual explainer for readers who want the story in a different rhythm.
Highlights
- AI redesigns antibodies for intracellular use
- Electrical charge key to antibody stability
- Intrabodies target neurodegenerative disease proteins
- Molecules shared freely for research
Transcript
Scientists redesigned 672 antibody fragments using AI to function inside human cells as intrabodies.
They identified electrical charge as key to antibody stability within cells, improving intracellular function.
These intrabodies can target proteins linked to Alzheimer’s, Parkinson’s, Huntington’s, and motor neurone disease.
The redesigned molecules will be freely available to researchers studying neurodegenerative diseases worldwide.
This breakthrough offers new tools to study disease proteins inside cells, advancing future treatment research.